Several initiatives aim to reduce the high costs of cancer R&D:
- Collaborative Research: Partnerships between academic institutions, governmental agencies, and pharmaceutical companies can share resources and expertise, reducing individual costs. - Adaptive Clinical Trials: These innovative trial designs allow for modifications based on interim results, potentially shortening the trial duration and reducing costs. - Regulatory Reforms: Streamlining regulatory processes and providing fast-track approvals for promising treatments can reduce time and expense.
